A Phase 1b, Single-Arm, Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), in Primary Membranous Nephropathy

budoprutug (TNT119) - Eliem Therap

Frank B. Cortazar, MD; William Bonificio, PhD; Naveen Daryani, PharmD; Stephen B. Thomas, PhD

Sep 23, 2024